Cepheid
Yossi Camu is an experienced business development executive in the pharmaceutical and biotechnology sectors, currently serving as the Vice President of Business Development & Strategic Alliances at Cepheid since March 2019. In this role, Yossi leads multiple collaborations focused on drug development, notably within the Covid-19 context. Previous positions include Co-Founder and Head of Business Development at Accuderm Sciences LLC, EVP of U.S. Business Development & Commercial Operations at Kamedis Ltd., and Senior Group Marketing Manager at Galderma. Yossi's extensive career at Johnson & Johnson included roles as Senior Division Manager and Group Product Director, managing high-revenue dermatology products. Educational qualifications include an MBA in Finance and International Business from NYU Stern School of Business and a BA in Economics from UCLA.
This person is not in any offices
Cepheid
9 followers
Cepheid is a molecular diagnostics company. The Company develops, manufactures and markets fully-integrated systems for testing in the Clinical and Non-Clinical markets. The Company's systems enable molecular testing for organisms and genetic-based diseases by automating otherwise complex manual laboratory procedures. The Company's systems integrate these steps and analyze biological samples in test cartridges. Its primary offering is the GeneXpert system, which integrates sample preparation in addition to Deoxyribonucleic acid (DNA) amplification and detection. The GeneXpert system is designed for a range of user types ranging from reference laboratories and hospital central laboratories to satellite testing locations, such as emergency departments and intensive care units within hospitals, as well as physician offices and other alternate site laboratories. It also offers the SmartCycler system, which integrates DNA amplification and detection to allow rapid analysis of a sample.